Overview
Automated Systems of Tacoma (AST) designs, builds, and services aseptic fill-finish machines for sterile injectable products and life sciences. Its equipment automates the process of filling and packaging ready-to-use nested vials, cartridges, and syringes under aseptic conditions, enabling reliable manufacturing of sterile products in pharmaceutical and biotechnology settings. The machines are designed to be flexible to accommodate different formats and regulatory requirements, and AST also offers ongoing service and support based on its five decades of experience in the field. Compared with competitors, AST emphasizes a long track record, close customer relationships, and a focus on tailoring high-automation equipment to meet stringent product and regulatory needs. The company’s goal is to provide dependable, adaptable aseptic processing solutions that help customers manufacture sterile products efficiently and in compliance with regulations.
Work here?Claim your company
Simplify's Take
What believers are saying
- AST and Marchesini debuted an expanded portfolio at INTERPHEX 2026, strengthening sales momentum.
- AST launched GENiSYS R accelerated delivery in July 2026, addressing urgent customer lead times.
- AST added COO Jacob Stephen and CCO Jon Lenihan, sharpening operations and commercial execution.
What critics are saying
- Marchesini's 44.39% stake makes AST dependent on a partner with strategic control.
- AST's niche aseptic equipment market faces pressure from larger packaging and robotics rivals.
- Any FDA validation failure on GENiSYS R, Shield GIT, or digital twin tools would cripple demand.
What makes Automated Systems of Tacoma unique
- AST's GENiSYS platform spans fill-finish automation, inspection, and digital twin tools.
- Marchesini Group bought 44.39% in December 2025, expanding AST's global sterile packaging reach.
- AST's 60-year Tacoma manufacturing base signals deep process know-how in aseptic equipment.
Help us improve and share your feedback! Did you find this helpful?